Abbott

MOLECULAR. IN MINUTES.™

ID NOW™ RAPID MOLECULAR TESTING

TRUSTED RESULTS DURING THE PATIENT ENCOUNTER

The ID NOW™ Platform provides highly sensitive test results in as few as **2–13 minutes**[1]

- **Fastest molecular** platform for infectious diseases[2]
- More sensitive than rapid antigen tests to **improve diagnostic accuracy**[3-6]
- Created for point-of-care **operational speed, clinical utility and timely patient care**
- CLIA-waived **intuitive procedure** allows for easy standardization across care settings
- **Bi-directional** connectivity and **remote upgrade** capability

ID NOW™ RESPIRATORY ASSAY MENU

COVID-19	**Influenza A & B**	**Strep A**	**RSV**
6–12 mins	5–13 mins[7]	2–6 mins[1]	≤ 13 mins

RAPID AND ACTIONABLE

RESULTS DURING THE PATIENT ENCOUNTER

The ID NOW™ Platform provides reliable real-time molecular test results in minutes to speed operations and optimize clinical utility in time-sensitive patient care settings.

UNCOMPROMISED MOLECULAR PERFORMANCE

INCREASE SENSITIVITY

Compared to antigen tests, molecular amplification generates billions of copies of the targeted genetic material to increase detection of even low-level infections.



INCREASE SPEED

The ID NOW™ Platform amplifies the sample using advanced proprietary isothermal technology to eliminate lengthy PCR temperature cycling and reduce isothermal processes for more timely and informed clinical decision-making.

Amplification Technology	PCR Polymerase Chain Reaction	ID NOW™ FASTEST AVAILABLE NEAR Nicking Enzyme Amplification Reaction	HDA Helicase-dependent Amplification	LAMP Loop-mediated Isothermal Amplification
Amplification	Thermocycling	Isothermal	Isothermal	Isothermal
Initial Amplification Step	Heat Cycles	Enzymes	Enzymes	Enzymes
Requires Temp Changes	Yes	No	No	No
TIME TO RESULTS[2]	15 mins–2+ hrs	**2–13 mins**	≥35 mins	≥60 mins

FLEXIBLE AND EFFICIENT

TESTING TO STREAMLINE CLINICAL WORKFLOW AND PATIENT CARE

Easily test based on clinical assessment and fluctuations in respiratory illnesses to optimize pretest probability

Align with diagnostic stewardship initiatives by delivering the right test, at the right time, to prompt the right action

SIMPLE AND SMART TECHNOLOGY

DESIGNED FOR ALL POINTS OF CARE

- Minimal training with color-coded reagents and on-screen video-guided operation
- Automated visually-displayed results to eliminate subjective test interpretation
- No complex sample handling or manual pipetting required
- Robust on-board software, and POC Link connectivity tool to enable streamlined remote software updates for ID NOW™ Instruments

THE POINT. IS CARE.

ORDERING INFORMATION

PRODUCT NAME	PRODUCT CODE	CPT® CODE†	MEDICARE RATE††
ID NOW™ INSTRUMENT	NAT-024		
ID NOW™ COVID-19 2.0 TEST KIT	192-000	87635	$51.31
ID NOW™ COVID-19 2.0 CONTROL KIT	192-080		
ID NOW™ COVID-19 2.0 SWAB TRANSPORT TUBE	190-010		
ID NOW™ INFLUENZA A & B 2 TEST KIT	427-000	87502	$95.80
ID NOW™ INFLUENZA A & B 2 CONTROL KIT	425-080		
ID NOW™ RSV TEST KIT	435-000	87634	$70.20
ID NOW™ RSV CONTROL SWAB KIT	435-080		
ID NOW™ STREP A 2 TEST KIT	734-000	87651	$35.09
ID NOW™ STREP A 2 CONTROL SWAB KIT	734-080		
ID NOW™ BARCODE SCANNER	L22XWU1200		
ID NOW™ UNIVERSAL PRINTER	IDNOWPRINT		

With COVID-19 + Flu Add-on Sequential Workflow*

CPT® CODE†
87636

MEDICARE RATE††
$142.63

Each test kit contains 24 tests, collection swabs and controls.

*Sequential workflow: Run the ID NOW™ COVID-19 2.0 followed by the ID NOW™ Influenza A & B 2 (each test sold separately). ID NOW™ software update to version 7.1 required.

CONTACT YOUR LOCAL ABBOTT REPRESENTATIVE
OR VISIT **GLOBALPOINTOFCARE.ABBOTT**

†Providers with a CLIA Certificate of Waiver should use the QW modifier when appropriate.
††2024 Medicare Clinical Laboratory Fee Schedule.
Current Procedural Terminology (CPT®) code information and current Medicare allowable reimbursement rates available at www.codemap.com/abbottpoc. As a courtesy to its customers, Abbott provides the most accurate and up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage of payment for our products or reimburse customers for claims that are denied by third party payors.

1. Abbott. ID NOW™ Strep A 2 Clinical Trial Data on File. **2.** Abbott. ID NOW™ Rapid Test Times to Result Analysis (v2.0). **3.** Fragkou PC, Moschopoulos CD, Dimopoulou D, et al; European Society of Clinical Microbiology and Infection Study Group for Respiratory Viruses. Performance of point-of care molecular and antigen-based tests for SARS-CoV-2: a living systematic review and meta-analysis. *Clin Microbiol Infect*. 2023;29(3):291-301. doi:10.1016/j.cmi.2022.10.028 **4.** Merckx J, Wali R, Schiller I, et al. Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis. *Ann Intern Med*. 2017;167(6):394-409. doi:10.7326/M17-0848 **5.** Cohen JF, Bertille N, Cohen R, Chalumeau M. Rapid antigen detection test for group A streptococcus in children with pharyngitis. *Cochrane Database Syst Rev*. 2016;7(7):CD010502. doi:10.1002/14651858.CD010502.pub2 **6.** Bernstein DI, Mejias A, Rath B, Woods CW, Deeter JP. Summarizing study characteristics and diagnostic performance of commercially available tests for respiratory syncytial virus: a scoping literature review in the COVID-19 era. *J Appl Lab Med*. 2022;8(2):353-371. **7.** Abbott. ID NOW™ Influenza A & B 2 Clinical Trial Data on File.

Abbott